Back to Search
Start Over
Development and use of ceramide nanoliposomes in cancer.
- Source :
-
Methods in enzymology [Methods Enzymol] 2012; Vol. 508, pp. 89-108. - Publication Year :
- 2012
-
Abstract
- Integration of C₆-ceramide into stealth pegylated nanoliposomes has led to the development of a promising preclinical therapeutic alone and in combination with other agents for treatment of cancer. Ceramide itself has been implicated as a bioactive lipid second messenger mediating cell senescence, cell cycle arrest, and apoptosis. Recent lipidomic analyses have demonstrated that specific ceramide species are differentially metabolized in individual cancers. Therapeutics that increase ceramide levels in cancer tissues have shown increased cell death and tumor inhibition. However, the use of ceramide itself as therapeutic has been problematic due to its inherent hydrophobicity and insolubility, therefore limiting the application for intravenous administration. Pegylated nanoliposomes eliminate this issue and are able to enhance the intracellular delivery of ceramide to cancer cells.<br /> (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Subjects :
- Animals
Antineoplastic Agents pharmacokinetics
Antineoplastic Agents pharmacology
Apoptosis drug effects
In Vitro Techniques
Maximum Tolerated Dose
Membrane Potentials
Mice
Neoplasms, Experimental metabolism
Neoplasms, Experimental pathology
Rats
Reactive Oxygen Species metabolism
Antineoplastic Agents administration & dosage
Ceramides administration & dosage
Drug Carriers
Liposomes
Nanoparticles
Neoplasms, Experimental drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1557-7988
- Volume :
- 508
- Database :
- MEDLINE
- Journal :
- Methods in enzymology
- Publication Type :
- Academic Journal
- Accession number :
- 22449922
- Full Text :
- https://doi.org/10.1016/B978-0-12-391860-4.00005-7